Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.06.11.20125849: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strengths and limitations: We used an open science community approach to design a set of analyses consistently applied across a network of observational databases to generate results that can be directly compared and interpreted in aggregate. These analyses employed active comparators to reduce confounding by indication and is the first to apply large-scale propensity adjustment with full diagnostics and a large set of negative control …
SciScore for 10.1101/2020.06.11.20125849: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strengths and limitations: We used an open science community approach to design a set of analyses consistently applied across a network of observational databases to generate results that can be directly compared and interpreted in aggregate. These analyses employed active comparators to reduce confounding by indication and is the first to apply large-scale propensity adjustment with full diagnostics and a large set of negative control experiments. We published the study protocol ahead of time and kept results blinded when assessing PS diagnostics helping to address concerns about reproducibility, robustness and transparency that have recently emerged (Rubin 2020; Mehra et al. 2020). We examined outpatient prevalent antihypertensive use because a new-user design in the context of COVID-19 that has widely affected the provision of routine care is infeasible. Therefore mediators on the causal pathway between exposure and outcome may be included in the adjustment. This may not necessarily result in bias in this setting however, as COVID-19 is a new illness and will not have affected the decision to initiate one drug over another and no depletion of susceptibles will have occurred. Similarly, biological mechanisms relating to ACE2 expression may require chronic exposure, hindering a new-user design. Prior treatment remains highly correlated with many baseline features that our large-scale propensity model considers when balancing patients and can provide some protection against t...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
